Recognized as one of the industry's most generous in-kind givers, we work with local governments, patient associations, humanitarian organizations and others to provide free treatment to hundreds of qualified patients in need each year.
Serious diseases do not discriminate; they affect people from all walks of life and in all economic circumstances. We recognize our responsibility to the patient community does not end with simply developing effective therapies. We are committed to helping those therapies reach patients who qualify, to the best of our ability, regardless of their ability to pay.
Partnerships for humanitarian aid
In developing countries, government and private health coverage may be nonexistent, or barely able to address basic medical care. For patients who require specialized treatment, care can be financially and logistically beyond their means. Our Humanitarian Programs have long provided several of our therapies for free to people who qualify in these situations, by managing the process ourselves and partnering with humanitarian organizations. We rely on our organizational partners—including Project HOPE, ANERA, Direct Relief, the World Federation of Hemophilia Humanitarian Aid Program, and others – for their local expertise and relationships, which help us support patients and navigate the challenges of reaching them.
Even in countries with established health systems, patients can still face delayed or limited coverage, reimbursement difficulties, or other circumstances that prevent their access to treatment. For such cases, our Humanitarian Programs provide our therapies free of charge to many qualified patients, while also working with governments and other local entities to help identify sustainable, long-term financial resources for treatment.
Learn more about our humanitarian partners
Helping patients around the world
Within our first year of having a commercial product in 1991, patients in the United States received access to free therapy. Since then, our humanitarian efforts have evolved and expanded to support five different lysosomal storage disorder (LSD) communities around the world and we’ve since broadened our program to include hemophilia patients.
The number of people living with LSDs is small—in the thousands or tens of thousands of people around the world. The number of LSD patients who receive free therapy through our Humanitarian programs often represents a significant percentage of the total population of people living with these diseases. To date, more than 700 LSD patients currently receive free therapy through our program. We have served more than 2,500 patients in 80+ countries since the program began, more than 250 of which have received free therapy for 10+ years.
Transforming humanitarian aid in hemophilia
We are committed to help transform the treatment of hemophilia in the developing world, where the vast majority of people with hemophilia have limited or no access to diagnosis and treatment and often don’t survive to adulthood due to lack of treatment. Together with Sobi™, we have pledged the single largest donation of hemophilia factor therapy in history.
In 2014, Sobi and Bioverativ, now part of Sanofi Genzyme, pledged to donate up to one billion IUs of factor over 10 years, including up to 500 million IUs to the World Federation of Hemophilia Humanitarian (WFH) Aid Program over a period of up to five years.
Today our Humanitarian Programs are meeting the needs of patients on six continents and include:
- International Charitable Access Program
- Charitable Access Program (U.S.)
- Gaucher Initiative (Egypt)
- India Charitable Access Program (India)
- China Charitable Access Program (China)
Reaching out to patients
Contact the Sanofi Genzyme U.S Charitable Access Program
Send us a message through our online form.